Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.54 USD
Change Today -0.11 / -6.67%
Volume 2.4M
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$1.62
Previous Close
$1.65
Day High
$1.63
Day Low
$1.53
52 Week High
04/25/14 - $2.87
52 Week Low
10/13/14 - $1.07
Market Cap
236.2M
Average Volume 10 Days
2.2M
EPS TTM
$-0.49
Shares Outstanding
153.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. It markets and sells its products to physicians, nurses, and other healthcare professionals. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

201 Employees
Last Reported Date: 03/11/15
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Chief Executive Officer, Interim Chief Commer...
Total Annual Compensation: $449.3K
President and Director
Total Annual Compensation: $370.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. Auditor Raises 'Going Concern' Doubt

Zogenix, Inc. filed its 10-K on Mar 11, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Zogenix Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Zogenix reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenues for the fourth quarter 2014, which consisted of net product revenue, contract manufacturing revenue, and service and other revenue, were $14.9 million, up 50% from $9.9 million in the fourth quarter 2013. Net loss for the fourth quarter 2014 was $20.5 million, or $0.14 per share compared to a net loss of $35.6 million, or $0.28 per share, for the fourth quarter 2013. Non-GAAP net loss adjusted for certain non-cash and non-recurring items for the fourth quarter 2014 was $0.13 per share compared to a loss of $0.13 per share for the fourth quarter 2013. Loss from operations was $27.062 million against $14.513 million a year ago. Net loss before income taxes was $20.482 million against $35.616 million a year ago. Total revenues for the full year 2014 were $40.5 million, up 23% from $33.0 million in the full year 2013. Net income for the full year 2014 was $8.6 million, or $0.06 per share compared to a net loss of $80.9 million, or $0.74 per share, for the full year 2013. Non-GAAP net loss adjusted for certain non-cash and non-recurring items for the full year 2014 was $0.65 per share compared to a loss of $0.54 per share for the full year 2013. Loss from operations was $20.039 million against $53.192 million a year ago. Net income before income taxes was $8.671 million against net loss before income taxes of $80.856 million a year ago.

Zogenix, Inc., Pernix Ireland Limited - M&A Call

To discuss its definitive agreement to acquire the Zohydro ER franchise from Zogenix, Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $1.54 USD -0.11

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $9.26 USD +0.05
Corium International Inc $9.00 USD -0.03
Durect Corp $2.11 USD -0.46
Egalet Corp $10.26 USD +0.05
Elite Pharmaceuticals Inc $0.25 USD +0.002
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings 27.9x
Price/Sales 6.1x
Price/Book 4.6x
Price/Cash Flow 29.5x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.